Jazz Pharmaceuticals PLC (JAZZ) Shares Bought by Nationwide Fund Advisors

Nationwide Fund Advisors lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 86.7% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 21,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,750 shares during the period. Nationwide Fund Advisors’ holdings in Jazz Pharmaceuticals PLC were worth $3,266,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. US Bancorp DE grew its stake in shares of Jazz Pharmaceuticals PLC by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 368 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals PLC by 43.0% during the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after acquiring an additional 295 shares during the last quarter. Gargoyle Investment Advisor L.L.C. purchased a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth about $206,000. Janney Montgomery Scott LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth about $211,000. Finally, Brighton Jones LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth about $213,000. Institutional investors and hedge funds own 88.34% of the company’s stock.

In other Jazz Pharmaceuticals PLC news, Director Paul L. Berns sold 662 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $142.37, for a total value of $94,248.94. Following the transaction, the director now directly owns 6,599 shares in the company, valued at approximately $939,499.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $154.97, for a total value of $30,994.00. The disclosure for this sale can be found here. Insiders sold a total of 9,297 shares of company stock worth $1,429,417 over the last quarter. Company insiders own 4.30% of the company’s stock.

JAZZ has been the topic of a number of research analyst reports. Stifel Nicolaus restated a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 30th. Mizuho lowered Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $162.00 to $150.00 in a research note on Tuesday, July 4th. Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. Deutsche Bank AG set a $178.00 price target on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Wells Fargo & Company restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $179.79.

ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Shares Bought by Nationwide Fund Advisors” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/10/11/jazz-pharmaceuticals-plc-jazz-shares-bought-by-nationwide-fund-advisors.html.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 143.57 on Wednesday. The firm has a market capitalization of $8.62 billion, a P/E ratio of 22.11 and a beta of 1.05. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The firm has a 50-day moving average price of $148.82 and a 200-day moving average price of $151.64.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. During the same quarter last year, the business posted $2.67 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current year.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

What are top analysts saying about Jazz Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jazz Pharmaceuticals PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit